FDA Commissioner Marty Makary and CBER Director Vinay Prasad published an article in JAMA on Tuesday outlining the FDA’s ...

After enduring multiple rounds of layoffs last year, Genentech’s employees are facing more uncertainty as the Roche unit lets ...

Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead ...

Guggenheim Partners called Insmed’s Phase IIb readout “impressive across the board,” with an efficacy profile that positions ...

The layoffs will heavily affect Vertex’s operations in Rhode Island, where the biotech will consolidate three facilities into ...

Gene therapies have ridden investor mania to huge valuations but commercialization challenges have pushed market caps to the ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

HHS Secretary Robert F. Kennedy Jr. made waves this week, firing the remaining members of the CDC’s Advisory Committee on ...

Some companies’ preferences for people who already have industry experience and the tough job market are among the hurdles ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

The company’s intein-based technology is initially aimed at Stargardt disease, a type of macular degeneration.

Despite substantial investments in groundbreaking treatments, companies struggle to communicate value early and to the right audience. Here’s how they can do better.